By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cancer molecular diagnostics firm MolecularMD announced today it has raised $6 million in a Series B equity financing round.

The financing will go toward accelerating the commercial launch of new platforms and related assay content in areas including next-generation sequencing and rare mutation detection, the Portland, Ore.-based firm said. Funds will also be directed at expanding its sales and marketing operations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.